id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0830-0030,FDA,FDA-2011-N-0830,"Agency Information Collection Activities; Proposals, Submissions, and Approvals: Announcement of Office of Management and Budget Approvals",Notice,Notice of Approval,2016-12-19T05:00:00Z,2016,12,2016-12-19T05:00:00Z,,2016-12-19T15:32:16Z,2016-30351,0,0,0900006482423485
FDA-2011-N-0830-0029,FDA,FDA-2011-N-0830,"Agency Information Collection Activities; Announcement of Office of
Management and Budget Approval; Abbreviated New Drug Applications
and 505(b)(2) Applications",Notice,Notice of Approval,2016-11-29T05:00:00Z,2016,11,2016-11-29T05:00:00Z,,2016-11-29T16:14:37Z,2016-28655,0,0,09000064823c607f
FDA-2011-N-0830-0027,FDA,FDA-2011-N-0830,"Reference 2-4 - U.S. Dept of Commerce, Bureau of the Census, Economic Census, Manuf Summary Series. General Summary Industry Stats for Subsectors and Industries by Employment Size 2007 re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T15:54:27Z,,0,0,09000064822a0d51
FDA-2011-N-0830-0024,FDA,FDA-2011-N-0830,"Reference 2 -1 - Final Regulatory Impact Analysis, Final Regulatory Flexibility Analysis, and Unfunded Mandates Reform Act Analysis for ANDAs and 505(b)(2) Apps; Final Rule re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T15:46:41Z,,0,0,09000064822a0aac
FDA-2011-N-0830-0022,FDA,FDA-2011-N-0830,Abbreviated New Drug Applications and 505(b)(2) Applications,Rule,Final Rule,2016-10-06T04:00:00Z,2016,10,2016-10-06T04:00:00Z,,2016-10-06T15:06:45Z,2016-22690,0,0,090000648229ee69
FDA-2011-N-0830-0028,FDA,FDA-2011-N-0830,"Reference 2-5 - U.S. Department of Health & Human Services, “Guidance on Proper Consideration of Small Entities in Rulemakings of the U.S. Department of Health and Human Services,” May 2003 re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T16:03:14Z,,0,0,09000064822a0d52
FDA-2011-N-0830-0025,FDA,FDA-2011-N-0830,Reference 2-2 - Bureau of Labor Statistics (BLS). 2016. May 2015 National Industry-Specific Occupational Employment and Wage Estimates for NAICS 325400 - Pharmal and Medicine Manufacturing,Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T15:50:38Z,,0,0,09000064822a0d4f
FDA-2011-N-0830-0023,FDA,FDA-2011-N-0830,"Reference 1 - Federal Trade Commission, Report on “Generic Drug Entry Prior to Patent Expiration  An FTC Study” (July 2002) re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T15:45:47Z,,0,0,09000064822a0aab
FDA-2011-N-0830-0026,FDA,FDA-2011-N-0830,"Reference 2-3 - U.S. Dept of Commerce, Bureau of the Census, Economic Census Manuf Summary Series. General Summary Industry Stats for Subsectors and Industries by Employment Size 2012 re Abbreviated New Drug Applications and 505(b)(2) Applications",Supporting & Related Material,Background Material,2016-10-06T04:00:00Z,2016,10,,,2016-10-06T15:53:02Z,,0,0,09000064822a0d50